- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
- Interventions
- GTAEXS617, SoC
- Drug
- Lead sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 1,499
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Interventions
- AU-007, Aldesleukin, Avelumab, Nivolumab
- Drug
- Lead sponsor
- Aulos Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
- Conditions
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Interventions
- Toripalimab, Paclitaxel
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cachexia, Squamous Cell Carcinoma
- Interventions
- Placebo Testosterone, Testosterone Enanthate 100 MG/ML
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Squamous Cell Carcinomas
- Interventions
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Radiation · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2035
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
- Interventions
- CP-383
- Drug
- Lead sponsor
- Tasca Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
- Conditions
- Oral Mucositis
- Interventions
- RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
- Drug · Radiation
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 11 more
- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Radiation
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
- Interventions
- TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab
- Drug
- Lead sponsor
- Tempest Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- NDURE
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
- Interventions
- INCAGN02385
- Biological
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- TAK-676, Carboplatin, 5-FU, Paclitaxel, TAK-676 + Carboplatin, Carboplatin + Paclitaxel, Carboplatin + 5-FU, TAK-676 + Carboplatin + 5-FU, TAK-676 + Carboplatin + Paclitaxel
- Drug · Combination Product
- Lead sponsor
- Presage Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Shreveport, Louisiana • The Bronx, New York • Cincinnati, Ohio + 1 more
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
- Interventions
- Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
- Procedure · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Laryngeal Cancer
- Interventions
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Drug · Radiation
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 4
- States / cities
- La Jolla, California • Bismarck, North Dakota • Fargo, North Dakota + 1 more
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Tisotumab Vedotin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- avelumab, Bempegaldesleukin, talazoparib, enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, stereotactic body radiation therapy
- Biological · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Head and Neck Cancer, Lung Cancer
- Interventions
- zileuton
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Head and Neck Cancer
- Interventions
- perifosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 12
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more